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The endothelial dysfunction of Fabry disease results from
a-galactosidase A deficiency leading to the accumulation of
globotriaosylceramide. Vasculopathy in the a-galactosidase A
null mouse is manifested as oxidant-induced thrombosis,
accelerated atherogenesis, and impaired arterial reactivity.
To better understand the pathogenesis of Fabry disease in
humans, we generated a human cell model by using RNA
interference. Hybrid endothelial cells were transiently
transfected with small interfering RNA (siRNA) specifically
directed against a-galactosidase A. Knockdown of
a-galactosidase A was confirmed using immunoblotting and
globotriaosylceramide accumulation. Endothelial nitric oxide
synthase (eNOS) activity was correspondingly decreased by
460%. Levels of 3-nitrotyrosine (3NT), a specific marker for
reactive nitrogen species and quantified using mass
spectrometry, increased by 40- to 120-fold without
corresponding changes in other oxidized amino acids,
consistent with eNOS-derived reactive nitrogen species as
the source of the reactive oxygen species. eNOS uncoupling
was confirmed by the observed increase in free plasma and
protein-bound aortic 3NT levels in the a-galactosidase A
knockout mice. Finally, 3NT levels, assayed in biobanked
plasma samples from patients with classical Fabry disease,
were over sixfold elevated compared with age- and
gender-matched controls. Thus, 3NT may serve as a
biomarker for the vascular involvement in Fabry disease.
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Fabry disease (FD) is an X-linked lysosomal storage disease
arising from a deficiency in a-galactosidase A (GLA). A loss
of GLA activity results in the accumulation of glycosphingo-
lipids with gala-1,4 gal linkages including globotriaosylcer-
amide (Gb3), galabiosylceramide, and globotriaosylsphingo-
sine (lyso-Gb3). FD has a pleiotropic phenotype that includes
renal disease, cardiomyopathy, and vasculopathy. The vascu-
lopathy is the basis for the life-threatening complications of
FD, including stroke, hypertrophic cardiomyopathy, and renal
failure. Whereas enzyme replacement therapy with recombinant
GLA has emerged as a therapeutic option for FD, its effective-
ness in preventing the long-term cardiovascular morbidities
has been questioned.1 The ability to evaluate and deliver
effective therapy is limited by a poor understanding of the
pathogenesis of the vasculopathy and by the absence of a
biomarker that corresponds directly with the presence and
degree of vascular dysfunction.
The Gla null mouse has been an useful model from explor-
ing the vascular pathophysiology of FD. Although this mouse
does not exhibit a spontaneous vascular phenotype, several
inducible models of vascular disease have been reported. These
include oxidant-induced thrombosis,2 accelerated atherogenesis,3
and impaired vasorelaxation.4 A common mechanism that
could potentially link these experimentally observed abnorma-
lities is endothelial nitric oxide synthase (eNOS) dysfunction.5
eNOS dysfunction may result in either decreased nitric oxide
(NO) bioavailability or enzyme uncoupling, which generates a
potent oxidant, peroxynitrite, a reactive nitrogen species.6,7 The
relationship between GLA and eNOS was explored by deter-
mining whether these changes could be recapitulated in a
human endothelial cell line. We report that when the Gb3
content of EA.hy926 cells is increased with GLA knockdown,
there is an associated uncoupling of eNOS with the formation
of 3-nitrotyrosine (3NT), a specific marker for reactive
nitrogen species. The eNOS dysfunction was specifically asso-
ciated with the loss of GLA activity in that comparable changes
were not observed with b-glucocerebrosidase (GBA) knock-
down. High circulating levels of 3NT were measured in the
plasma and aortic extracts of Gla knockout mice.
Finally, the concentrations of protein-bound oxidized
amino acids were measured in plasma samples from classic
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FD patients and compared with age- and gender-matched
controls. A more than fivefold elevation in 3NTwas observed
in the FD samples compared with controls, raising the
possibility that 3NT represents an useful biomarker for
vasculopathy in FD.
RESULTS
EA.hy926 cell studies
Previous work in GLA-deficient mice demonstrated en-
dothelial dysfunction associated with decreased NO bioavail-
ability and eNOS uncoupling.5 To determine whether similar
abnormalities could be documented in a human vascular
endothelial cell line, immortalized EA.hy926 cells, derived
from fused HUVEC and A549 cells, were employed. EA.hy926
cells retain endothelial characteristics, including Factor VIII-
related antigen expression, eNOS gene expression, and
Weibel–Palade bodies.8,9 Importantly, EA.hy926 cells also
are characterized by measureable Gb3 and GLA (Figure 1a
and b).
The silencing efficacies of Dicer-substrate RNAs (dsiRNA)
(27-mer) and traditional small interfering RNA (siRNA) (21-
mer) were assessed to determine whether it would be possible
to fully suppress the expression and activity of GLA in
cultured EA.hy926 cells. The conventional 21-mer siRNA
against human GLA demonstrated low efficiency and short
blocking times (data not shown). By contrast, anti-human
GLA-dsiRNA completely knocked down GLA in cultured
EA.hy926 cells for up to 3 days at a relatively low siRNA
concentration (10 nM) as confirmed using immunoblotting
(Figure 1a). As both siRNA and dsiRNA interference are
transient, a second transfection was performed 3 days later.
Under these conditions, GLA silencing was observed up to
day 6. The lower expression of GLA was associated with the
accumulation of Gb3 (Figure 1b). A correlation between
increased Gb3 and the degree of GLA knockdown was
observed. Compared with control-dsiRNA–transfected cells,
the Gb3 levels in GLA-dsiRNA–transfected cells increased
with the duration of the incubation with GLA-dsiRNA,
ranging from 210% of control on day 2 after a single
transfection up to 275% on day 6 with a double transfection
(Figure 1c).
The specificity of the Gb3 changes was evaluated by use of
GBA-dsiRNA. GBA encodes b-glucocerebrosidase, the lyso-
somal glycosidase that degrades glucosylceramide (GlcCer) to
ceramide. GBA expression in cultured EA.hy926 cells was
suppressed to undetectable levels. The silencing effect lasted
until day 6 as measured using immunoblotting (Figure 2a).
This silencing effect was observed following both single
transfection and double transfection with the 27-mer anti-
human GBA-dsiRNA. The corresponding loss of GBA
activity resulted in the accumulation of GlcCer (Figure 2b).
The specificity of this effect was demonstrated by the absence
of any corresponding change in galactosylceramide, a
cerebroside that is not a substrate for GlcCerase.
GlcCer mass increased fivefold in GBA-dsiRNA–trans-
fected cells relative to the levels in control-dsiRNA cells
(Figure 2c). A small but reproducible reduction in GlcCer
from its peak level occurred on day 4 after first transfection
likely due to transient effect of siRNA. When a double GBA-
dsiRNA transfection was performed, the cellular GlcCer levels
on day 6 were as high as those observed on day 3 with a single
transfection (Figure 2c). Although GlcCer is a precursor in
Gb3 synthesis, no increase in Gb3 levels were observed in cells
subjected to GBA-dsiRNA transfection (Figure 2d and e).
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Figure 1 | Alpha-galactosidase A (GLA) knockdown raises
globotriaosylceramide (Gb3) in a time-dependent manner. (a) A
representative immunoblot for complete knockdown of the GLA
from cultured EA.hy926 cells by three anti-human GLA-dsiRNA (Dicer-
substrate RNA) duplexes (D1, D2, D3) at the indicated exposure times.
(b) A representative thin layer chromatogram of neutral sphingolipids
demonstrating Gb3 accumulation in GLA-dsiRNA–transfected
EA.hy926 cells harvested on days 2 and 3 after a single transfection
(ST) and on day 5 and 6 after double transfections (DT), respectively.
LacCer, lactosylceramide; SM, sphingomyelin; Std., standards. (c) Gb3
levels in EA.hy926 cells as determined by scanning densitometry with
the ImageJ software (NIH, Bethesda, MD). The values were
normalized to Gb3 levels in cells transfected with a non-targeting
control-dsiRNA. The data represent the mean±s.e. from six
independent experiments. *Po0.01.
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Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
was silenced with GAPDH-dsiRNA to evaluate the effects
of transfection on endothelial cell phenotype, morphology,
oxidant stress, and viability because of either nonspecific or
specific gene knockdown. GAPDH expression in EA.hy926
cells was lowered 498% by GAPDH-dsiRNA as measured
using immunoblotting. A double transfection enhanced and
prolonged the interference of GAPDH expression up to 6
days (Figure 3a). Cell numbers and viability following
transfections were measured daily. The growth curve showed
a similar recovery and growth pattern in cells transfected with
control, GBA, and GAPDH-dsiRNAs. However, GLA-dsiRNA
transfection was associated with lower growth and increased
cell detachment from cultured dishes (Figure 3b). Forty
percent of the detached cells remained viable and metabo-
lically active as measured by trypan blue exclusion.
Gla knockout mouse studies
Previous investigations uncovered the high levels of 3NT and
ortho-tyrosine formation in mouse aortic endothelial cells
isolated from Fabry mice, demonstrating that oxidant stress
is characteristic of the Fabry mouse aortic endothelial cell
phenotype.5 The levels of protein-bound oxidatively modified
amino acids were quantified using tandem mass spectrometry
in cultured EA.hy926 cells transfected with GLA-dsiRNA
(Gene 1), GBA-dsiRNA (Gene 2), and GAPDH-dsiRNA
(Gene 3), respectively. Low levels were detectable in control-
dsiRNA–transfected EA.hy926 cells and served as basal levels.
3NT, a specific marker for reactive nitrogen species, was
markedly elevated (40- to 120-fold) in GLA-dsiRNA–transfected
cells (Figure 4a) without corresponding changes in other
oxidized tyrosines, including 3-chlorotyrosine, ortho-tyro-
sine, meta-tyrosine, and o,o0-dityrosine (Figure 4b), consis-
tent with the mouse model of FD.5 Double GBA-dsiRNA
transfection modestly increased 3NT formation. However,
this change was not associated with Gb3 accumulation in that
GBA-dsiRNA transfection did not raise Gb3 under any
conditions (Figure 2d and e), and also not related with
repeated siRNA reagents usage, as double GAPDH-dsiRNA
transfection did not increase nitrotyrosine production
compared with that in single GAPDH-dsiRNA–transfected
EA.hy926 cells (Figure 4a).
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GBA (b-glucocerebrosidase) gene and suppression of
b-glucocerebrosidase, another lysosomal hydrolase, in cultured
EA.hy926 cells by three duplexes of anti-human GBA-dsiRNA
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as confirmed using immune bot analysis. (b) Lipids analysis of
the glucosylceramide (GlcCer) levels in control-dsiRNA and GBA-
dsiRNA–transfected EA.hy926 cells on days 3 and 4 of following a
single transfection (ST) and on day 6 following a double transfection
(DT). GalCer, galactosylceramide; Std., standards. (c) Determination of
GlcCer accumulation in control- and GBA-dsiRNA–transfected cells by
densitometric scanning (n¼ 3). (d) Levels of Gb3 in GBA–siRNA-
transfected cells assessed in parallel using high-performance thin
layer chromatography, and (e) as determined using scanning
densitometry (n¼ 3). The error bars represent±s.e. *Po0.01.
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eNOS activity was next measured in GLA-dsiRNA–transfected
cells. As shown in Figure 5a, eNOS activity correspondingly
decreased in the EA.hy926 cells, and the reduction was
460% on day 3 following the first GLA-dsiRNA transfection
and 490% on day 6 following the second GLA-dsiRNA
transfection. No difference was found in GBA- and GAPDH-
dsiRNA–transfected cells with control-dsiRNA–transected
cells (Figure 5b), consistent with a specific effect of Gb3
accumulation on eNOS activity.
3NT levels in plasma samples were measured using mass
spectrometry in the GLA knockout mouse. A statistically signi-
ficant increase in 3NT formation (100% vs. 171%) was
observed between 2-month-old wild-type and Gla-/0 mice
(Figure 6). A more significant elevation of nitrotyrosine (431%)
in 9-month-old Gla-/0 mice was measured compared with wild-
type mice at the same age, consistent with the age-dependent
accumulation of Gb3 in the vasculature. Nine-month-old
wild-type mice had a 45% higher level of nitrotyrosine in the
plasma than their 2-month-old counterparts.
Protein modification by nitration of tyrosine to 3NT has
been correlated with elevated oxidative stress.10 Immunoblots
of aortic homogenates demonstrated higher levels of 3NT in
aortas dissected from Gla null compared with wild-type mice
at 2 and 8 months of age (Figure 7a). A sixfold increase in
3NT formation in the older Gla null mouse aortas compared
with wild-type aortas was confirmed using scanning densito-
metry (Figure 7b).
3-Nitrotyrosine measurements in Fabry patients
Biobanked plasma samples from 13 male Fabry patients were
analyzed for oxidized amino acids including 3NTand compared
with 11 control samples that were age- and gender-matched
from the same biobank. Affected patients had classical
symptoms of FD including acroparasthesias, cornea verticil-
lata, and angiokeratomas in association with low or absent
GLA activity, increased levels of plasma Gb3, and high
concentrations of plasma lyso-Gb3 (Table 1).
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Figure 3 | Interference of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) expression and effect on cell viability in
transfected cells. (a) EA.hy926 cells were transfected with three anti-
human GAPDH-dsiRNA (Dicer-substrate RNA) duplexes (A, B, and C)
at indicated concentration for indicated days. Harvested cells were
lysed in 1% Triton X-100 lysate buffer and analyzed using western
blot. Upper panel, a representative immunoblot of GAPDH
knockdown in cultured EA.hy926 cells. Lower panel, immunoblot for
b-actin. (b) The number of viable transfected EA.hy926 cells were
counted and recorded daily based on trypan blue exclusion. All
experiments were repeated for three times with three different
batches of cell cultures under similar conditions. ST, single
transfection; DT, double transfection.
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Figure 4 | Oxidant stress is characteristic of the Fabry human
endothelial cell phenotype. (a) Comparison of nitrotyrosine content
in cultured EA.hy926 cells transfected, respectively, with GLA (alpha-
galactosidase A)–dsiRNA (Dicer-substrate RNA) (n¼ 4), GBA (b-
glucocerebrosidase)-dsiRNA (n¼ 4), and GAPDH (glyceraldehyde 3-
phosphate dehydrogenase)–dsiRNA (n¼ 3) as measured using liquid
chromatography–electrospray ionization tandem mass spectrometry
(LC/ESI/MS). The results were normalized to the protein content of
tyrosine, the precursor of 3-nitrotyrosine. (b) Levels of other oxidant
amino acids; chlorotyrosine (Chloro-Y), ortho-tyrosine (Ortho-Y),
meta-tyrosine (Meta-Y), and dityrosine (Di-Y) in endothelial cells
transfected twice with either control-dsiRNA or GLA-dsiRNA as
analyzed using LCE-ITMS (n¼ 3).
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A more than sixfold elevation in 3NT concentration was
observed in the Fabry cohort compared with the age-matched
controls. No significant differences in the concentrations of
chlorotyrosine, dityrosine, or ortho- or meta-tyrosine were
measured between the two groups (Figure 8 and Table 2). No
correlation was observed between the 3NT levels and the
eGFRs, ages, plasma Gb3, or plasma lyso-Gb3 levels of
the Fabry group (Supplementary Figures S1–S3 online).
These measurements are consistent with eNOS uncoupling
and resultant elevated reactive nitrogen species in untreated
patients with classical FD.
DISCUSSION
Milestones in FD research included the discovery of the
lysosome by de Duve and Wattiaux,11 the recognized loss of
GLA activity by Kint,12 and the association of lysosomal
inclusions in endothelial cells and smooth muscle cells of the
vasculature by Hashimoto et al.13 Subsequent work by
Sweeley and Klionsky14 and Brady et al.15 documented that
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the disease was due to a deficiency of GLA with the
accumulation of globo series glycosphingolipids.
The use of recombinant GLA as enzyme replacement
therapy is the standard of care for the treatment of FD. For
several reasons, the benefits of enzyme replacement therapy
for FD have been difficult to prove.16,17 First, the time from
diagnosis to a clinically meaningful outcome for FD is long.
Decades often pass from the onset of symptoms before
significant events such as stroke or renal failure occur.
Second, study populations have usually been small, including
patients in different disease stages. Finally, there are a limited
number of biomarkers of FD and none are yet proven to be
directly related to the pathogenesis of the vasculopathy.
Establishing a mechanism for the vascular disease and sub-
sequently a nexus between a biomarker and the progression
of the vasculopathy would clearly be a valuable advance in the
prospective management of these patients.
Two primary hypotheses have been proposed for the
pathogenesis of the vasculopathy of FD. The first hypothesis
proposes that circulating lyso-Gb3 deposits in the medial
layer of the arterial vasculature promoting smooth muscle
cell proliferating and modeling of the subendothelial layer. A
resultant increase in shear stress results in increased
expression of angiotensin receptors with subsequent forma-
tion of reactive oxygen species and NF-kB activation. These
changes then lead to a decrease in NO synthesis and increase
in b-integrin expression. The basis for this hypothesis has
been recently reviewed.18
An alternative hypothesis proposes that eNOS dysregula-
tion is the causal basis for Fabry-associated vasculopathy and
that Gb3 accumulation in the endothelium alone is sufficient
to account for the dysregulation of eNOS with lower NO
bioavailability and eNOS uncoupling with the formation of
reactive oxidants. This hypothesis is supported by the
identification of three inducible models of vasculopathy in
the Gla knockout mouse. When arterial injury was induced
by the release of reactive oxygen species using rose Bengal,
Gla knockout mice exhibited a highly robust sensitivity to
carotid thrombosis.2 This sensitivity correlated with the age
of the mice as well as arterial Gb3 deposition. In another
model, Gla knockout mice were bred on an apoE1-deficient
background. Forty-five-week-old mice demonstrated a
marked increase in atherosclerosis compared with Gla mice
on a normal background.3 In a third model, aortic rings from
Table 2 | Plasma oxidized amino acid concentrations
Fabry disease (n¼ 13) Controls (n¼ 11)
3-Nitrotyrosine 37.8 (13.6–86.0)* 6.5 (1.7–14.0)
Chlorotyrosine 12.2 (0.03–74.5) 10.0 (0.04–50.3)
Dityrosine 15.2 (12.6–19.5) 16.3 (12.9–21.0)
Meta-tyrosine 18.7 (0.1–68.3) 21.9 (0.01–72.9)
Ortho-tyrosine 23.2 (9.6–49.7) 18.0 (7.4–86.1)
The oxidized amino-acid concentrations were assayed as described in the Materials
and Methods section. The data are expressed as mmol/mmole of total protein
tyrosine and represent medians (range) of triplicate assays performed twice per
sample. *Po0.01.
Table 1 | Fabry disease and control patient characteristics
Fabry disease
n (%) or median
(range)
Controls
n (%) or median
(range)
Males 13 (100) 11 (100)
Age 42.7 (16.8–53.7) 49.4 (20.4–60.5)
AGAL-A activity % 0.05 (0–2.8) ND
GLA mutations
Missense 5
Nonsense, frame 6
Shift/splice site 2
Plasma Gb3 6.3 (5.3–9.74) n¼ 10 ND
Lyso-Gb3 82.3 (152.7–150.3) n¼ 9 ND
Age of diagnosis (year) 21.5 (12–41)
Classical symptoms
Acroparesthesia 12
Cornea verticillata 12 (n¼ 12)
Angiokeratoma 11
Organ involvement
eGFR 95.5 (26–152) 99.8 (83–126)
LVH 5 (n¼ 12) ND
Stroke/TIA 3 0
Myocardial infarct/
CABG
0 0
ACE/ARB use 3 0
Cardiovascular risk factors
Diabetes mellitus 0 0
Hypertension 3 (n¼ 12) 1
Dyslipidemia 0 1
Smoking 5 (n¼ 12) 3
Obesity 0 2
Abbreviations: ACE, angiotensin I converting enzyme inhibitor; AGAL-A, alpha-
galactosidase A activity (relative to the mean reference value in healthy controls in
leucocytes); ARB, angiotensin II receptor blockers; CABG, coronary artery bypass
graft; eGFR, estimated glomerular filtration rate; GLA, alpha-galactosidase A; LVH,
left ventricular hypertrophy; Lyso-Gb3, globotriaosylsphingosine; ND, not determined;
TIA, transient ischemic attack.
Age and eGFR were not significantly different between Fabry and control groups
based on a non-parametric t-test was used.
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wild-type and Gla null mice were pre-contracted with pheny-
lephrine. The Gla-deficient rings demonstrated impaired
relaxation to acetylcholine.4 The defect was eliminated with
calcium ionophore-stimulated endothelial relaxation, consis-
tent with an abnormality in the plasma membrane of the
endothelium. Primary cultures of aortic endothelial cells were
employed to further document that increased plasma
membrane Gb3 was the basis for the abnormality.19,20 The
Gb3 content of Gla knockout endothelial cells was markedly
elevated in the total plasma membrane as well as the caveolar
fractions. This increase was associated with decreased eNOS
expression, hormone-stimulated eNOS activity, and levels of
high molecular weight caveolin-1 oligomers.21 These obser-
vations were consistent with a role for Gb3 in the assembly of
the signalsome within caveolae, including eNOS. These
experimental models of thrombosis, atherogenesis, and
impaired relaxation identify eNOS dysregulation as a likely
basis for the inducible models of vasculopathy.
Clinical studies attempting to assess the role of NO have
been less consistent but in aggregate support a role for eNOS
dysregulation. For example, comparing flow-mediated dila-
tion of the brachial artery in Fabry patients and healthy
controls, two studies have documented decreased arterial
flow in the Fabry group.22,23 This finding was confirmed
using venous occlusion plethysmography and superficial index
finger skin blood flow using laser Doppler flowmetry.24,25 In
other studies, decreased coronary blood flow has been
measured in Fabry patients.26,27 However, another group
has demonstrated increased forearm blood flow in FD with
acetylcholine infusion that persisted even when eNOS was
inhibited by L-NMMA.28
Studies on cerebral blood flow have also yielded conflict-
ing results reporting either decreased29 or enhanced flow.30
These seemingly contradictory findings may potentially be
explained by eNOS uncoupling with secondary oxidative
stress, resulting in protein nitration. A potential role for
eNOS uncoupling is supported by a study of skin micro-
vascular endothelial cells in which Gb3 loading resulted in an
increase in reactive oxygen species. Gb3 loading was also
associated with an increase in the transcription of
intercellular adhesion molecule 1, vascular cellular adhesion
molecule 1, and E-selectin.31
The current study addressed whether induced changes in
Gb3 content in an endothelial cell line would be sufficient
to account for eNOS dysregulation. EA.hy926 cells were
employed. Conditions suitable for the reproducible loss of
GLA activity by siRNA were established, and the secondary
accumulation of Gb3 was documented. Under these condi-
tions, there was a decrease in eNOS activity consistent with
the impaired formation of NO. Concurrently, eNOS
uncoupling with reactive nitrogen species formation was
observed as measured by the formation of 3NT but not of
other tyrosine adducts. These changes were not observed
when GBA activity was similarly depressed.
Previous studies have highlighted a role for plasma 3NT as
a marker for established cardiovascular disease in humans.32,33
To further establish whether 3NT might be a suitable marker
of vasculopathy in FD, mouse plasma from GLA knockout
and wild-type mice were assayed and compared. 3NT levels
were markedly increased and were further elevated in older
knockout mice. Parallel changes in 3NTwere measured in the
mouse aortas. The absence of significant increases in ortho-
tyrosine, meta-tyrosine, dityrosine, and chlorotyrosine in
mouse plasma or aortic samples from the Gla null mice
suggests that eNOS uncoupling alone is sufficient to account
for the reactive oxygen species formed.34
Finally, 3NT levels were measured in biobanked plasma
samples from untreated patients with classic FD. A robust
and statistically significant increase in 3NT concentrations
was measured in the absence of comparable changes in other
oxidized amino acids. These findings suggest that eNOS
uncoupling is likely present in human GLA deficiency and is
a potential biomarker that directly correlates with a func-
tional vascular abnormality. This finding requires confirma-
tion with prospective clinical studies involving larger
numbers of patients, including those with non-classical
forms of the disease. If elevated plasma 3NT levels reflect
the degree of vascular involvement in FD, then future studies
may better define the role for 3NT in establishing the
prognosis of the disorder, the risk to patients for developing
vascular complications, and possibly the efficacy of current
therapies designed to reduce Gb3. Importantly, the ability to
demonstrate eNOS uncoupling directly by the measurement
3NT in an in vitro endothelial cell culture model, the Gla
knockout mouse, and in patients with FD also provides a
platform for the identification of more effective therapies.
MATERIALS AND METHODS
Mice
Wild-type C57BL/6 and Gla-deficient Fabry mice were housed and
genotyped as described previously.5 Animal studies were conducted
in accordance with the University of Michigan Committee on the
Use and Care of Laboratory Animals.
Cell cultures
EA.hy926 cells were purchased from ATCC (Manassas, VA).
EA.hy926 cells are a human umbilical cell line established by the
fusion of primary human umbilical vein cells with a thioguanine-
resistant clone of A549 cells.9 EA.hy926 cells were maintained in
complete growth medium consisting of Dulbecco’s Modified Eagle
Medium/F12 (1:1, v/v)/GlutaMAX (Life Technologies, Grand Island,
NY), 10% fetal bovine serum, 100U/ml penicillin, and 100mg/ml
streptomycin, and subcultured twice weekly at a ratio of 1:5.
RNA interference
Anti-human siRNA oligonucleotides were predesigned and synthe-
sized by Origene Technologies (Rockville, MD). The ID numbers
for GLA, GBA, and GAPDH siRNAs were SR301812, SR301748,
and SR301734, respectively. Each siRNA kit contained three
Dicer-substrate 27-mer duplexes (dsiRNA). Stock concentrations
of the siRNAs were made at 20 mM in RNase-free reconstitution
buffer consisting of 100mM potassium acetate and 30mM
HEPES (pH 7.5). Reconstituted siRNAs were heated at 94 1C for
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2min and then cooled to room temperature before storage at
 20 1C.
One day before siRNA transfection, 8105 EA.hy926 cells were
seeded into a 100-mm culture dish containing 8ml of complete
growth medium. The transfection mixture was prepared immediately
before addition. Briefly, LipofectamineRNAiMAX (Life Technologies)
was diluted into 1ml of Opti-MEM-I according to the manufacturer’s
guidelines, and the siRNA duplex was diluted with 1ml of
Opti-MEM-I at indicated final concentration. The dilution media
were combined and incubated at room temperature for 20min to
form the siRNA/transfection reagent complex. The culture medium
was replaced with 8ml of Opti-MEM-I without serum and
antibiotics, and the siRNA complex was gently dropped into the
cell culture. After an 8-h transfection period, serum fetal bovine
serum was added to attain a final concentration of 3%. On the
second day of transfection, the Opti-MEM-I medium was replaced
by complete growth medium. A second siRNA transfection was
performed on day 4 following the first transfection as detailed above.
The transfected EA.hy926 cells were harvested at the indicated days
for immunoblotting, lipid, amino acid, or cell viability analyses.
Lipid analysis and western blotting
Glycosphingolipid analyses followed procedures previously described.20
Immunoblot analysis of EA.hy926 cells followed previously published
protocols.5 For analysis of GLA knockdowns, rabbit anti-human GLA
monoclonal antibody (LifeSpan BioSciences, Seattle, WA) was used at a
dilution of 1:2500 (0.5mg/ml). 3NT levels in mouse aortic lysates were
analyzed with mouse anti-mouse 3NT monoclonal antibody (Abcam,
Cambridge, MA) at a dilution of 1:2000 (0.4mg/ml).
Analysis of oxidized amino acids
Cells or tissue samples were washed and homogenized in Buffer A
consisting of 100 mM diethylenetetraminopentaacetic acid, 50 mM
butylated hydroxytoluene, 10 ml/ml Halt protease inhibitor (Pierce,
Rockford, IL) in 50mM sodium phosphate buffer, pH 7.4.
Homogenized cellular proteins were precipitated with ice-cold
10% trichloroacetic acid and delipidated with water/methanol/
water-washed diethyl ether (1:3:7; vol/vol/vol). Known concentra-
tions of isotopically labeled internal standards including 13C6
tyrosine, 13C6 phenylalanine and
13C6 ortho-tyrosine,
13C6 o,o
0-
dityrosine, 13C6 3NT and
13C6 3-chlorotyroine were added, and
samples were hydrolyzed for 24 h in 4N methane sulfonic acid
supplemented with 1% benzoic acid. The hydrolysate was
subjected to reverse-phase extraction with Supelclean ENVI ChromP
columns (3ml, Supelco, Bellefonte, PA). Oxidized amino acids were
quantified using liquid chromatography–electrospray ionization
tandem mass spectrometry in the multiple reaction monitoring
mode as described previously.5 The ratio of the peak areas of the
analytes with corresponding 13C6 internal standards were used to
quantify levels of the analytes. Results were normalized to the
content of tyrosine, the precursor of 3NT, 3-chlorotyrosine and o,o’-
dityrosine, or to phenylalanine, the precursor for ortho- and meta-
tyrosine.35
eNOS activity measurements
Cellular eNOS activities in control-siRNA and GLA-siRNA–trans-
fected EA.hy926 cells were measured following an adopted protocol
as described previously.5
Mouse tissue preparation
Mouse blood was withdrawn from the retro-orbital sinus using a
Microvette EDTA-coated capillary blood collection tubes (Fisher
Scientific, Pittsburgh, PA). The blood (120ml) was immediately
centrifuged at 1500g for 15min at 4 1C. Fifty microliter of plasma
was recovered and stored at  80 1C for analysis of oxidized amino
acids. Mouse aortas from wild-type and GLA null mice trans-
fections were stored in antioxidant solution buffer A at  80 1C.
Well-minced mouse aortas were homogenized with a Tissue Tearor
(Biospec Products, Bartlesville, OK) and lysed in 1% Triton X-100
lysate buffer. The clarified aorta lysate was analyzed with the help of
immunoblotting after BCA assay.
Human participants
Oxidized amino-acid levels were assayed from biobanked plasma
samples from the Academic Medical Center in Amsterdam that
included those from classical male FD patients. FD was diagnosed by
GLA deficiency (defined as GLA activity o5% relative to the mean
reference value in healthy controls) and by GLA genotyping36 and
the presence of elevated lyso-Gb3 levels.37 Classical FD was defined
as described in reference 38. Baseline plasma lyso-Gb3 and plasma
Gb3 were previously determined as described in references39 using
reference values for lyso-Gb3 of 0.3–0.5 nmol/l and for plasma Gb3
of 1.08–3.18mmol/l. Left ventricular hypertrophy was defined as an
interventricular septal thickness in diastole of 412mm. The
glomerular filtration rate was estimated by CKD-EPI creatinine
equation (eGFR). Plasma samples from 14 patients with classical FD
were initially identified. However, one Fabry patient sample (with
the highest measured 3NT) was excluded from the analysis upon
determination that at the time of sampling the patient was recover-
ing from cardiogenic shock with acute renal failure. The FD patients
were age- and gender-matched to healthy controls, derived from an
earlier study that included patient relatives with an excluded
diagnosis of FD based on GLA genotyping, friends of the subjects, or
subjects recruited by advertisement.40 All FD and control subjects
provided informed consent. The study conformed to the declaration
of Helsinki and was conducted under institutional review board
approvals at the Academic Medical Center of Amsterdam and the
University of Michigan.
Statistical analysis
Cell data were analyzed using the Prism software (GraphPad,
La Jolla, CA) using t-test or two-way analysis of variance and are
expressed as mean±s.e.m. Differences between control and treated
samples were considered statistically significant at a P-value o0.05.
Statistical analyses on patient samples were performed using SPSS.
Constant variables are presented as medians (ranges). Differences
between control and FD subjects were compared using non-
parametric tests. Correlations between 3NT levels and patient
characteristics were compared using Spearman’s rank tests. Po0.05
was considered significant.
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